UBS analyst Jacob Navin raised his price target on Madrigal Pharmaceuticals to $143 as part of his reinstated coverage but also kept his Neutral rating, saying he prefers to wait for a better entry point because of its "few near term catalysts" and high consensus expectations. The analyst states after failed Selonsertib trial and Ocaliva "not achieving a home-run scenario", the upside case for the stock can be made only if the phase 3 trial for MGL-3196 is positive on dual endpoints in "Fibrosis improvement & NASH resolution" and also shows clean safety.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here